<unk>  is a hedgehog pathway inhibitor indicated, in combination with low-dose cytarabine that is FDA approved for the treatment of newly-diagnosed acute myeloid leukemia (AML) in adult patients who are ≥75 years old or who have comorbidities that preclude use of intensive induction chemotherapy. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include anemia, fatigue, hemorrhage, febrile neutropenia, musculoskeletal pain, nausea, edema, thrombocytopenia, dyspnea, decreased appetite, dysgeusia, mucositis, constipation, and rash.
Glasdegib
Sdasdfadfasf
Remikiren
Bergapten
Crofelemer
Selexipag
Lucinactant
Insulin lispro